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Introduction {#sec1}
============

The balance between cell proliferation and apoptosis plays a fundamental role during development and tissue homeostasis. Perturbations in this balance often lead to cancer or degenerative diseases. The Hippo signaling pathway is an evolutionarily conserved kinase cascade that has been established as a key regulator of organ size and tissue homeostasis ([@bib61], [@bib19], [@bib38]) in *Drosophila* and mice. Core components of this pathway include the Hippo kinase (Hpo or MST1/2 in mammals), which phosphorylates and activates Warts (Wts or LATS1/2 in mammals), which in turn phosphorylates and inactivates the transcriptional coactivator Yorkie (Yki or YAP/TAZ in mammals) by targeting it for nuclear export and degradation ([@bib61], [@bib19], [@bib38]). Yki/YAP/TAZ trigger the transcription of target genes, the best characterized of which either promote cell proliferation or suppress apoptosis and thereby affect tissue growth ([@bib38]). Abnormally elevated YAP/TAZ levels and nuclear enrichment of these proteins have been observed in various human cancers ([@bib61], [@bib19]), while hyperactivation of Hpo promotes apoptosis ([@bib39], [@bib53]), suggesting that proper control of Hippo signaling is crucial for tissue homeostasis. As transcriptional coactivators that lack a DNA-binding domain, Yki/YAP must interact with the DNA-binding transcription factors, namely Scalloped (Sd or TEAD1-4 in mammals), to effect target gene expression ([@bib13], [@bib58], [@bib64], [@bib67]). Genome-wide chromatin-binding analyses revealed that many of the effects of Yki/YAP/TAZ on transcriptional activity occur via distal enhancers ([@bib47], [@bib62], [@bib37]), suggesting that Yki/YAP/TAZ recruit various transcription factors, chromatin modulators, or epigenetic markers to regulate expression of their targets. This idea has been confirmed in recent studies that showed Yki/YAP/TAZ can interact not only with Sd/TEADs family proteins but also with GAGA factors, SWI/SNF complex subunits, Nuclear receptor coactivator 6 (Ncoa6), and the ecdysone receptor coactivator Taiman (Tai) in various tissue contexts ([@bib63], [@bib68], [@bib41], [@bib45], [@bib18], [@bib37]). It also has been shown that the Tondu-domain-containing growth inhibitor (Tgi) (VGLL4 in mammals) directly competes with Yki for Sd binding, resulting in inhibition of Yki-regulated transcription ([@bib14], [@bib22]). In mammals, VGLL4 competes with YAP for TEAD4 binding via a similar mechanism ([@bib66]). In the presence of active Hippo signaling, the lack of nuclear Yki/YAP allows Tgi/VGLL4 to complex with Sd/TEADs and promotes transcriptional repression. When Hippo signaling is silenced, Yki/YAP translocate into the nucleus and displace Tgi/VGLL4 from Sd/TEADs, leading to transcriptional activation and tissue growth ([@bib22]). These studies yielded a model in which Sd/TEADs could act as a platform for integrating different signal inputs to regulate tissue homeostasis. Since Hippo signaling has been found to cross-talk with multiple pathways in a context-dependent manner ([@bib61]), we may consider Hippo signaling as a complex network rather than a single linear pathway. However, how Hippo signaling might synergize or compete with other signaling and transcription control systems that affect cell proliferation and survival remains obscure.

The RB-E2F pathway has long been known as a critical regulator of cell-cycle progression. In this system, RB binds to E2F/Dp complexes and recruits chromatin and histone regulators to E2F-regulated promoters for repression of target genes ([@bib48]), many of which promote cell proliferation. Functional inactivation of RB relieves the repression from E2F/Dp complexes, which in turn promote cell-cycle progression. RB has been established as a tumor suppressor that normally suppresses cell proliferation. In addition, its activity affects cell differentiation and rates of apoptosis ([@bib4]). Inactivation of Rb in mouse embryo induced aberrant apoptosis that can be inhibited by E2F1 deficiency, demonstrating a function as a suppressor of E2F1-mediated apoptosis ([@bib52]). Indeed, ectopic expression of E2F1 leads to apoptosis in *Drosophila*, cultured cells, and transgenic mice ([@bib54]). Consistently, E2F1 knockout mice show higher rates of tumor development and lower rates of thymic apoptosis ([@bib33]). In contrast, RB can also act in a pro-apoptotic manner by functioning in a transcriptionally active RB/E2F1 complex that promotes expression of pro-apoptotic genes in highly proliferative cells ([@bib11]). These studies suggest that the ability of RB/E2F1 to regulate tissue homeostasis (growth versus apoptosis) may be dictated by the cellular context, although its precise mechanisms of control are less well defined.

In this study, we found that *Drosophila* E2F1 and RBF regulate apoptosis via interactions with Hippo signaling, and thereby affect organ size and tissue homeostasis. Analysis of this interaction revealed that E2F1 competes with Yki for binding to Sd, and that this competition affects the expression of the Yki target genes *Diap1*, *expanded (ex)*, and *bantam (ban)*. Besides these classical Yki targets, our DamID-seq and RNA-seq data define a set of Yki targets that can be negatively regulated by E2F1. Gene ontology analysis showed that these genes play diverse roles during development and tissue homeostasis, suggesting that E2F1/Yki competition is a broad phenomenon. Furthermore, our data show that RBF levels affect the output of this competition and indicate that the mechanism is conserved in human cells, where YAP, E2F1, and TEAD1 show analogous interactions. In summary, our study uncovers a previously unknown mechanism in which RBF/RB regulates Hippo signaling by modulating the balance of Yki/Sd (or YAP/TEAD1 in human cells) activator and E2F1/Sd (or hE2F1/TEAD1 in human cells) repressor complexes.

Results {#sec2}
=======

*Drosophila* RBF Positively Regulates Yki Target Genes {#sec2.1}
------------------------------------------------------

To identify new regulators for organ size control, we performed an RNAi screen in which we scored for alterations of *Drosophila* wing size. In the screen, we found that RNAi-mediated depletion of *Rbf* using *nubGal4* resulted in the formation of abnormally small wings with normal wing vein patterning ([Figures 1](#fig1){ref-type="fig"}A--1B). Similarly, knockdown of *Rbf* using *enGal4* reduced wing size specifically in the posterior compartment ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1A′), and *Rbf*^*14*^*/Rbf*^*14*^ homozygous mutant eyes generated by the EGUF/hid method ([@bib49]) were significantly reduced in size ([Figures 1](#fig1){ref-type="fig"}C and 1C′). In the developing larval wing, *Rbf*-depleted cell clones displayed significantly reduced size ([Figure 1](#fig1){ref-type="fig"}D), as also shown in [@bib10]. These observations indicate that *Rbf* is essential for normal cell and tissue growth. Although this is surprising when one considers RBF's function in restraining cell proliferation ([@bib6]), it is consistent with previous reports from *Drosophila* ([@bib50], [@bib10]) that suggest that *Rbf* mutant cells are sub-viable.Figure 1*Drosophila* RBF Positively Regulates Yki Target Genes(A and A′) Adult wing size: (A) *nubGal4/+* control, (A′) *Rbf* knockdown driven by *nubGal4*. The pictures were taken under the same magnification.(B) Quantification of adult wing sizes of control versus *Rbf*^*RNAi*^ (mean ± SD, n = 5, t test, ^∗∗∗^p \< 0.001).(C and C′) Adult eye of *Rbf*^*14*^*/+* (C) and *Rbf*^*14*^*/Rbf*^*14*^ (C′) flies.(D) Quantification of clone area of flip-out clones: control versus *Rbf*^*RNAi*^ (mean ± SD, n = 34, t test, ^∗∗^p \< 0.01).(E--F′) *Diap1-lacZ* expression in control (E) and *Rbf* knockdown (F and F′) wing discs. (F′) anterior compartment marked by Cubitus interruptus (Ci) staining.(G--G″) *Rbf* overexpression in the posterior compartment was driven by *hhGal4, tubGal80*^*ts*^ (*hh*^*ts*^). The larvae were raised at 18°C, and then shifted to 29°C for 48 hr before dissection in third-instar stage. Nuclei were stained by DAPI. (G″) Fluorescent intensity of ex-lacZ in the anterior compartment versus the *RBF*-overexpressed posterior compartment was measured by ImageJ. The mean values represent the expression levels of ex-lacZ. Statistical analysis shows significant enhancement of ex-lacZ levels in the *RBF*-overexpressed posterior compartment (mean ± SD, t test, n = 5, ^∗∗∗^p \< 0.001).(H--H″) *UAS-Rbf*^*RNAi*^ and *UAS-E2f1*^*RNAi*^ were coexpressed using *enGal4*.White asterisks (F, G, and H) indicate the normal expression levels of each indicated reporter in anterior compartments. Yellow asterisks (F, G, and H) indicate the altered expression levels of each reporter upon different indicated genetic manipulations in posterior compartments.

In investigating RBF's growth regulatory function, we tested interactions with Hippo/Yki signaling, a highly conserved pathway that also regulates cell proliferation and organ size. We first investigated whether RBF is required for the expression of Yki target genes. In the wing disc, RNAi depletion of *Rbf* led to a significant reduction in the expression of *Diap1-lacZ* ([Figures 1](#fig1){ref-type="fig"}E--1F′), a well-characterized Yki target. Knockdown of *Rbf* using *mirrGal4* in the dorsal part of the eye disc also reduced *Diap1-GFP* expression ([Figure S1](#mmc1){ref-type="supplementary-material"}B). Consistently, overexpression of *CycD/Cdk4*, whose kinase activity can inactivate RBF ([@bib8]), also suppressed the expression of *Diap1-lacZ* ([Figure S1](#mmc1){ref-type="supplementary-material"}C). Conversely, overexpression of *Rbf* significantly increased the expression of *Diap1-GFP* ([Figures S1](#mmc1){ref-type="supplementary-material"}D and S1D′) and another Yki target, *ex-lacZ* ([Figures 1](#fig1){ref-type="fig"}G--1G″). Thus, RBF regulates the expression of Yki target genes.

E2F1/Dp Negatively Regulates Yki Target Genes {#sec2.2}
---------------------------------------------

Given that a major function of RBF is to act as a corepressor for the E2F1 and E2F2 transcription factors, we examined whether RBF regulated Hippo signaling in an E2F-dependent manner. We found that the reduction of *Diap1-GFP* induced by the depletion of *Rbf* could be reversed by *E2f1* knockdown ([Figures 1](#fig1){ref-type="fig"}H--1H″). This suggests that RBF could affect organ size through E2F1 and Yki. Further tests showed that overexpression of *E2f1* significantly decreased levels of *Diap1-GFP* ([Figures 2](#fig2){ref-type="fig"}A--2B′). However, overexpression of *E2f2*, a non-essential paralog of *E2f1* that acts as a repressor, showed no effect on *Diap1-GFP* expression ([Figure S1](#mmc1){ref-type="supplementary-material"}E), suggesting a specific role for E2F1. We then investigated the suppressive effect of E2F1^PIP3A^, a stabilized but active form of E2F1 ([@bib69]), on Yki activity. Overexpressed *E2f1*^*PIP3A*^ strongly reduced the expression of *Diap1* as indicated by *Diap1-lacZ* and Diap1 staining ([Figures S1](#mmc1){ref-type="supplementary-material"}F--S1F″).Figure 2E2F1/Dp Negatively Regulates Yki Target Genes(A) *Diap1-GFP* expression in control wing disc.(B and B′) The larvae were raised at 18°C and then shifted to 29°C for 72 hr before dissection in third-instar stage. Overexpression of *E2f1* in posterior part (indicated by yellow asterisk in B) of wing discs using *hh*^*ts*^. Anterior compartment labelled by a white asterisk.(C--E′) *UAS-E2f1+Dp*-overexpressing clones were generated using the MARCM system. (C) Quantification of clone area of MARCM clones: control versus *E2f1+Dp* (1,587 ± 182.0 versus 158.1 ± 49.12, mean ± SD, t test, ^∗∗∗^p \< 0.001). (D--E′) Diap1 staining in control (D and D′) and *E2f1+Dp* overexpression (E and E′) wing discs. Yellow asterisk (D) indicates Diap1 in a control MARCM clone, while the white asterisk (D) indicates Diap1 expression outside of the control MARCM clone. Arrowheads in (E) indicate reduced Diap1 levels in a *E2f1+Dp*-overexpressing clone.(F and F′) *ex-lacZ* levels were detected in flip-out clones overexpressing *E2f1+Dp*. Arrowheads in (F) showed the reduction of *ex-lacZ*.(G and G′) *E2f1* overexpression was driven by *enGal4*. Red asterisk in (G) indicated the decreasing of *ban-lacZ*. White asterisk in (G) indicates the normal levels of *ban-lacZ* in the anterior compartment.(H and H′) *GFP-E2f1* was overexpressed using *enGal4*.(I and I′) *UAS-GFP-E2f1* and *UAS-Dp*^*RNAi*^ were coexpressed using *enGal4*. White asterisks (H and I) label the normal expression of *diap1-lacZ* in anterior compartments, while the yellow asterisks indicate expression of *diap1-lacZ* upon the indicated genetic manipulations in posterior compartments.Scale bars, 20 μm.

Next, we performed a MARCM clone assay to investigate whether *E2f1* overexpression might inhibit tissue growth in the wing disc. Cell clones overexpressing *E2f1* and *Dp* grew significantly less than wild-type controls ([Figures 2](#fig2){ref-type="fig"}C--2E′), and the expression of *Diap1* in these clones was reduced, suggesting that the transcriptional activity of Yki was suppressed ([Figure 2](#fig2){ref-type="fig"}E). Consistent with this, clones overexpressing *E2f1+Dp* showed less *ex-lacZ* expression ([Figures 2](#fig2){ref-type="fig"}F and 2F′). Overexpression of *E2f1* also led to a significant reduction in the expression of *ban-lacZ* ([Figures 2](#fig2){ref-type="fig"}G and 2G′), another established target of Yki ([@bib36], [@bib51]). Since E2F1 requires complex formation with Dp to function, we asked whether the E2F1-mediated suppression of Yki targets was Dp-dependent. As expected, knockdown of *Dp* blocked the inhibitory effect of E2F1 on the expression of *Diap1-lacZ* ([Figures 2](#fig2){ref-type="fig"}H--2I′). These results demonstrate that E2F1 suppresses Yki activity in a Dp-dependent manner.

Yki-E2F1 Epistasis {#sec2.3}
------------------

We next investigated the epistatic relationships between E2F1 and Hippo pathway components. We found that depletion of *hpo* using RNAi did not affect the reduction in *Diap1-GFP* expression caused by *E2f1+Dp* overexpression ([Figures 3](#fig3){ref-type="fig"}A and 3A′). This suggests that the suppression of Yki target gene expression by E2F1 occurs downstream of Hpo. We checked whether the transcription of the Yki dimerization partner, *scalloped* (*sd*) might be regulated by E2F1. However, levels of *sd-lacZ* were not affected by ectopic *E2f1+Dp* ([Figures 3](#fig3){ref-type="fig"}B and 3B′), suggesting that E2F1 does not suppress Yki activity by controlling *sd* expression. Interestingly, in cells overexpressing *E2f1+Dp*, protein levels of Yki were reduced ([Figures 3](#fig3){ref-type="fig"}C--3D′), despite a lack of change in levels of *yki* mRNA ([Figure 3](#fig3){ref-type="fig"}E). Knockdown of *E2f1*, however, caused no detectable change in the protein levels of Yki ([Figures 3](#fig3){ref-type="fig"}F and 3F′). This observation suggested that overexpression of *yki* might rescue the *E2f1* overexpression phenotype. Indeed, overexpression of a constitutively active mutant version of Yki, Yki^S168A^, reversed the loss of *ex-lacZ* expression caused by high levels of *E2f1* ([Figures 3](#fig3){ref-type="fig"}G--3H′). Taken together, these data indicate that E2F1 acts in parallel or upstream of Yki to regulate the expression of Hippo pathway targets (e.g., *Diap1* and *ex*).Figure 3Yki-E2F1 Epistasis(A--B′) The larvae were raised at 18°C. (A and A′) *UAS-E2f1+Dp* and *UAS-hpo*^*RNAi*^ were coexpressed using *hhGal4*. Yellow asterisk in (A) indicates the decrease of *Diap1-GFP* expression. White asterisk (A) indicates normal expression levels of *diap1-GFP* in the anterior compartment.(B and B′) *UAS-E2f1+Dp* was overexpressed using *hhGal4*. Transcription levels of sd were indicated by *sd-lacZ* reporter. White asterisk in (B) indicates the normal expression levels of s*d-lacZ* in the anterior compartment.(C and C′) Larvae were raised at 18°C and then shifted to 29°C for 48 hr before dissection in third-instar stage. *UAS-P35* and *UAS-E2f1+Dp* were coexpressed using *hh*^*ts*^. P35 was coexpressed to block the potential side effect that apoptosis induces universal reduction of total protein levels. The reduction of Yki protein levels is indicated by a red asterisk in (C). The yellow asterisk indicates the normal expression of Yki in the anterior compartment.(D and E) Larvae were raised at 18°C and then shifted to 29°C for 48 hr before dissection in third-instar stage. The control and *E2f1+Dp* overexpression (driven by *nubGal4, tubGal80*^*ts*^, henceforth referred to as *nub*^*ts*^) wing discs were dissected for western blot and qRT-PCR. (D′) The relative levels of Yki as shown in (D) were quantified after normalization against actin. Values represent mean ± SEM (n = 3, t test, ^∗^p \< 0.05).(F--F″) *UAS-E2f1*^*RNAi*^ was overexpressed using *enGal4*. Anterior/posterior boundary in (F) is shown by the dotted line.(G and G′) Larvae were raised at 18°C, and then shifted to 29°C for 48 hr before dissection in third-instar stage. (G and G′) *GFP-E2f1* overexpression was driven by *hh*^*ts*^. The decrease of *ex-lacZ* is indicated by the red asterisk. Yellow asterisk in (G) indicates normal expression of *ex-lacZ* in the anterior compartment.(H and H′) *UAS-GFP-E2f1* and *UAS-yki*^*S168A*^ were coexpressed using *hh*^*ts*^. The *E2f1*-induced *ex-lacZ* reduction (red asterisk in G) was reversed by *yki*^*S168A*^ overexpression (yellow asterisk in H). White asterisk in (H) indicates normal expression of *ex-lacZ* in the anterior compartment.

We next investigated the effects of loss of *E2F1* function on the expression of Yki targets. In *E2f1*-depleted cells, the expression of either *Diap1-GFP* ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2A′) or *ex-lacZ* ([Figures S2](#mmc1){ref-type="supplementary-material"}C and S2C′) was increased. Similarly, knockdown of *Dp* also significantly increased the expression of *Diap1-GFP* ([Figures S2](#mmc1){ref-type="supplementary-material"}B and S2B′). Further, the upregulation of *ex* caused by *E2f1*-RNAi could be reversed by depletion of *yki* ([Figures S2](#mmc1){ref-type="supplementary-material"}D and S2D′). Moreover, the upregulation of *Diap1* caused by *hpo* knockdown ([Figures S2](#mmc1){ref-type="supplementary-material"}E and S2E′) or *yki* overexpression ([Figures S2](#mmc1){ref-type="supplementary-material"}G and S2G′) could be strengthened by coexpression of *E2f1*-RNAi ([Figures S2](#mmc1){ref-type="supplementary-material"}F and S2F′ and [Figures S2](#mmc1){ref-type="supplementary-material"}H and S2H′, respectively). Overall these results are consistent with the conclusion that E2F1 acts as a repressor of Yki target gene expression.

In the course of these experiments we also discovered that the expression of an *E2f1* transcriptional reporter, *e2f1-lacZ* ([Figure S2](#mmc1){ref-type="supplementary-material"}I), E2F1 protein ([Figure S2](#mmc1){ref-type="supplementary-material"}J), and the E2F1 target gene *PCNA-GFP* ([Figures S2](#mmc1){ref-type="supplementary-material"}K and S2K′) were all upregulated by *yki* overexpression. These results confirm previous observations suggesting that *E2f1* is a downstream target of Hippo signaling ([@bib13], [@bib35]). In the context of our other results, this relationship suggests that Yki might negatively regulate its own activity by stimulating E2F1 expression. This kind of regulation, wherein a transcriptional activator indirectly suppresses its own targets, is not infrequent in nature and has been termed "incoherent" regulation.

E2F1 DNA Binding Is Required for Interaction with Yki/Sd {#sec2.4}
--------------------------------------------------------

We next examined the biochemical basis underlying E2F1's suppression of Yki activity. We found that both E2F1 and Dp could be coimmunoprecipitated (coIPed) with Yki's transcriptional coactivator, Sd from S2 or HEK293 cells ([Figures 4](#fig4){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}A). However, no direct interaction was detected between E2F1 and Yki ([Figures 4](#fig4){ref-type="fig"}B and [S3](#mmc1){ref-type="supplementary-material"}B). Interestingly, overexpression of E2F1 reduced the amount of Yki pulled down by Sd ([Figure 4](#fig4){ref-type="fig"}C), and conversely, overexpression of Yki diminished the amount of E2F1 pulled down by Sd ([Figure 4](#fig4){ref-type="fig"}D). Moreover, increasing concentrations of E2F1 decreased the amount of Yki bound to Sd ([Figure S3](#mmc1){ref-type="supplementary-material"}C). These results indicate that E2F1 can compete with Yki for Sd interaction. This competition mechanism is similar to that reported for Tgi, which was demonstrated to play a role in Sd-mediated default repression ([@bib14], [@bib22]). Hence, we reasoned that, if E2F1 uses a similar mechanism, knockdown of *sd* should relieve the suppression of Yki targets by E2F1. Confirming this prediction, knockdown of *sd* partially reversed the reduction of *Diap1-lacZ* caused by overexpressed *E2f1* ([Figures S3](#mmc1){ref-type="supplementary-material"}D--S3E′). These results suggest that E2F1 competes with Yki for Sd interaction and is required for Sd-mediated default repression of *Diap1* in the wing disc. Furthermore, overexpression of *Rbf* diminished the amount of E2F1 pulled down by Sd ([Figure S4](#mmc1){ref-type="supplementary-material"}F), suggesting that RBF reflects the competition of E2F1 and Yki for Sd interaction.Figure 4E2F1 DNA Binding Is Required for Interaction with Yki/Sd(A--C) The indicated plasmids were transfected into *Drosophila* S2 cells (A--C) and HEK293T cells (D and F), respectively, for coIP assays. E2F1 coIPed with HA-Sd (A) rather than with My-Yki (B). (C) Overexpression of E2F1 diminished the amount of Myc-Yki pulled down by HA-Sd.(D) Overexpression of Myc-Yki reduced the interaction between E2F1 and HA-Sd.(E) Sequence alignment of the DNA-binding domains of *Drosophila* E2F1 (dE2F1) and human E2F1 (hE2F1) with DNAMAN software, followed by manual refinement.(F) To create the E2F1^E259^ mutant, the DNA sequence at *Drosophila* E2F1 codons L259 and G260 (CTGGGA) were replaced with an EcoRI restriction site sequence (GAATTC). *E2F1*^*D296A*^ was generated using the site-directed mutagenesis system. Neither E2F1^E259^ nor E2F1^D296A^ was pulled down by HA-Sd.(G--I′) Compared with wild-type E2F1 (G and G′), neither E2F1^E259^ (H and H′) nor E2F1^D296A^ (I and I′) showed suppression on the expression of *Diap1-GFP*.(J) Schematic representation of the *Diap1* loci and a putative binding site of RBF/E2F1. The binding of RBF/E2F1 on *Diap1* was analyzed based on published data ([@bib37], [@bib23]). *Diap1-lacZ*^*2B*^, but not *Diap1-lacZ*^*2B2C*^, contained this binding site.(K--L′) Overexpression of *E2f1* was driven by *hhGal4*, respectively. The levels of *Diap1-lacZ*^*2B*^ (K and K′), rather than *Diap1-lacZ*^*2B2C*^ (L and L′), was decreased by E2F1 overexpression. White asterisks (K and L) indicate the normal expression of each indicated reporter in anterior compartments, whereas yellow asterisks (K and L) indicate the altered expression of each reporter upon *E2f1* overexpression in posterior compartments. Dotted line in (L) indicates the anterior/posterior compartment boundary.(M and N) ChIP assays were performed in *Drosophila* S2 cells transfected with indicated plasmids. Chromatins were precipitated by control IgG or Myc antibody. The enrichment of ChIP products on the intronic Hippo-responsive element (HRE) of *diap1* and *ex* promoter were measured by real-time PCR (mean ± SEM, n = 3, t test, ^∗^p \< 0.05, ^∗∗∗^p \< 0.001, ns, not significant).

We next tested whether the DNA-binding activity of E2F1 is required for its repression of Yki activity. In previous studies in mammalian cells, the L132 site of human E2F1 was reported to be essential for DNA binding and activation ([@bib9]). By sequence alignment analysis, amino acid hE2F1^L132^ was found to be conserved as E2F1^L259^ in *Drosophila* ([Figure 4](#fig4){ref-type="fig"}E). The DNA sequence at *Drosophila* E2F1 codons L259 and G260 was replaced with an EcoRI restriction site sequence (here designated as E2F1^E259^). In addition, E2F1^D296^, which is conserved with hE2F1^D169^, is required for DNA binding and transcriptional activation in *Drosophila* ([@bib43]). A D296 to A296 point mutation of E2F1 (E2F1^D296A^) was generated. In coIP assays, neither E2F1^E259^ nor E2F1^D296A^ were pulled down efficiently with HA-Sd ([Figure 4](#fig4){ref-type="fig"}F). Furthermore, overexpression of either *E2f1*^*D296A*^ or *E2f1*^*E259*^ did not suppress *Diap1-GFP* expression ([Figures 4](#fig4){ref-type="fig"}G--4H′, [S3](#mmc1){ref-type="supplementary-material"}H, and S3H′). By chromatin immunoprecipitation (ChIP) assays, we found that overexpression of wild-type *E2f1* significantly reduced the Yki binding on the intronic Hippo-responsive element (HRE) of *diap1* ([Figure 4](#fig4){ref-type="fig"}M) and the promoter region of *ex* ([Figure 4](#fig4){ref-type="fig"}N). However, *E2f1*^*D296A*^ lost the repression of Yki binding on *Diap1* and *ex* ([Figures 4](#fig4){ref-type="fig"}M and 4N). These results demonstrate E2F1's DNA-binding domain is required for it to interact with Sd and suppress Yki target genes.

Further, we undertook to map the interacting region on E2F1 and Sd. CoIP data showed that both HA-Sd^N^, which contains the DNA-binding domain of Sd, and HA-Sd^C^, which lacks the DNA-binding domain, could interact with E2F1 ([Figure S3](#mmc1){ref-type="supplementary-material"}G). This surprising result indicates that the DNA-binding domain of Sd is not required for its interaction with E2F1. Moreover, through analyzing published E2F1 and RBF ChIP data from third-instar larvae ([@bib23]), we found a potential binding site of RBF/E2F1, which is close to the intronic HRE of *Diap1* ([Figure 4](#fig4){ref-type="fig"}J). Hence, we tested whether a reporter gene that lacks this RBF/E2F1 binding site but still has Sd binding sites could be regulated by E2F1. [@bib58] generated such constructs. The longer form of their reporter, *Diap1-lacZ*^*2B*^, contains the potential RBF/E2F1 binding site, while the shorter form of the reporter, *Diap1-lacZ*^*2B2C*^, lacks this site ([Figure 4](#fig4){ref-type="fig"}J). Consistent with our expectation, we found that the expression of *Diap1-lacZ*^*2B*^ but not *Diap1-lacZ*^*2B2C*^ could be suppressed by *E2f1* overexpression ([Figures 4](#fig4){ref-type="fig"}K--4L′). To determine if the competition between E2F1 and Yki depends on the transactivating function of E2F1, we generated a truncation mutant of the transactivation domain of *E2f1*, *E2f1*^*TDM*^, in which the Q525 was mutated to a stop codon ([@bib43]). We found that *E2f1*^*TDM*^ could interact with HA-Sd by coIP ([Figure S3](#mmc1){ref-type="supplementary-material"}I), and that overexpressed *E2f1*^*TDM*^ could suppress *Diap1-GFP* ([Figures 4](#fig4){ref-type="fig"}I and 4I′). By further *in vitro* binding assay, we found that E2F1 physically binds to Sd, and Yki could diminish this physical interaction ([Figure S3](#mmc1){ref-type="supplementary-material"}J). These results indicate that the competition effect and the binding of E2F1 to Sd do not require E2F1's transactivation domain.

To further investigate the potential interactions between Yki and E2F1 on target gene promoters, published E2F1 ChIP-chip data from third-instar larvae ([@bib23]) and Yki ChIP-seq data from third-instar wing discs ([@bib37]) were analyzed. The nearest promoter for each binding peak was determined according to FlyBase gene annotation. Compared with randomized peaks distributed in the *Drosophila* genome, both Yki binding peaks and E2F1 binding peaks were enriched in promoter regions ([Figure S4](#mmc1){ref-type="supplementary-material"}A). Focusing on genes targeted by both Yki and E2F1 (i.e., both Yki and E2F1 peaks detected within a ±1 kb region surrounding their transcription start sites), Yki and E2F1 peaks were significantly overlapped according to a Jaccard index calculation ([Figure S4](#mmc1){ref-type="supplementary-material"}B). Overall, these data indicate that E2F and Yki/Sd bind adjacent sites in the vicinity of target gene promoters. This genomic colocalization may facilitate the competition between E2F1/Dp and Yki/Sd that affects target gene expression.

E2F1/Sd Interactions Modulate Apoptosis {#sec2.5}
---------------------------------------

Since loss of *Rbf* function reduced wing and eye sizes, RBF may play a role in cell survival during organ development. We found that knockdown of *Rbf* induced obvious apoptosis in wing discs, as indicated by cleaved caspase-3 staining ([Figures 5](#fig5){ref-type="fig"}A and 5A′). This apoptosis could be suppressed by simultaneous *E2f1* knockdown ([Figures 5](#fig5){ref-type="fig"}B and 5B′), suggesting that *Rbf* loss promotes apoptosis by potentiating E2F1. Consistent with this and a previous report ([@bib32]), overexpression of *E2f1+Dp* caused significant cell death in wing discs ([Figures 5](#fig5){ref-type="fig"}C and 5C′). Interestingly, this phenotype was significantly diminished by *sd* knockdown, suggesting that E2F1 may induce apoptosis by interacting with Sd ([Figures 5](#fig5){ref-type="fig"}D and 5D′). This led us to ask whether E2F1 triggers cell death via its DNA-binding activity. Indeed, the E2F1^E259^ DNA-binding mutant had a greatly reduced ability to induce apoptosis ([Figures 5](#fig5){ref-type="fig"}E--5E″), indicating that DNA binding of E2F1 is required. Further, overexpression of *diap1* successfully restored the reduced clone size caused by *E2f1+Dp* overexpression ([Figure 5](#fig5){ref-type="fig"}F), indicating that the reduction in clone size was likely due to increased apoptosis. Taken together, our data are consistent with a model in which RBF/E2F1-regulated apoptosis depends on the balance of pro-apoptotic E2F1/Sd complexes and anti-apoptotic Yki/Sd complexes.Figure 5E2F1/Sd Interactions Modulate Apoptosis and Intestinal Stem Cell Proliferation(A--B′) Larvae were raised at 18°C and then shifted to 29°C for 48 hr before dissection in third-instar stage. *Rbf* knockdown or *Rbf*/*E2f1* double knockdown was driven by *nub*^*ts*^. Apoptosis was detected by caspase-3 staining.(C--D′) Larvae were raised at 18°C and then shifted to 29°C for 36 hr before dissection in third-instar stage. *E2f1+Dp* overexpression or *E2f1+Dp* overexpression in conjunction with *sd* knockdown was driven by *nub*^*ts*^, respectively. Apoptosis was detected by caspase-3 staining.(E--E″) E2F1^E259^ lost the ability to induce apoptosis.(F) Quantification of clone area of flip-out clones expressing different transgenes as indicated. Values represent mean ± SD (t test, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001, ns, not significant).(G--J) Adult females were shifted to 29°C after eclosion for 3 days and midguts were stained with anti-GFP and anti-PH3 antibodies and DAPI. The enterocyte (EC)-specific driver, *myo1A-Gal4*, *tubGal80*^*ts*^, *UAS-GFP* (*myo1A*^*ts*^*,GFP*), was used to drive the expression of each of the transgenes shown in (G). ECs were labeled by GFP. Intestinal stem cell (ISC) mitosis was scored and quantified by PH3^+^ cells. Nuclei in (H, I, and J) were stained by DAPI. Quantification data shown in (G) represents the mean ± SD (t test, ^∗∗^p \< 0.01, ^∗∗∗∗^p \< 0.0001, ns, not significant).

E2F1/Sd Interactions Modulate Intestinal Stem Cell Proliferation {#sec2.6}
----------------------------------------------------------------

Given that Hippo signaling plays critical roles in regulating intestinal stem cell (ISC) division during normal midgut homeostasis and regeneration ([@bib20], [@bib42], [@bib44], [@bib46], [@bib31]), we addressed the relevance of E2F1 to Hippo signaling during this process. As widely documented in previous studies ([@bib15], [@bib16]), the apoptosis of midgut enterocytes (ECs) stimulates cytokine (Upd2, 3) and growth factor (Vn, Spi, Krn) production that non-cell autonomously triggers ICS mitoses and accelerates midgut turnover. Since *E2f1* overexpression can induce apoptosis in many cell types, we investigated whether E2F1 non-cell autonomously regulates ISC mitosis by modifying Hippo signaling. Overexpression of *E2f1+Dp* in ECs, which are post-mitotic, robustly triggered the division of ISCs ([Figure 5](#fig5){ref-type="fig"}G). In addition, the number of mature GFP^+^ ECs was significantly reduced compared with wild-type control ([Figures 5](#fig5){ref-type="fig"}H and 5I). These observations are consistent with the induction of EC apoptosis by *E2f1+Dp* overexpression. Although RNAi-mediated depletion of *sd* in ECs had no detectable effect on ISC proliferation ([Figure 5](#fig5){ref-type="fig"}G), depletion of *sd* in ECs overexpressing *E2f1+Dp* significantly suppressed the non-cell autonomous stimulation of ISC proliferation induced by *E2f1+Dp* ([Figures 5](#fig5){ref-type="fig"}G and 5J). These results are consistent with those we obtained in wing discs and further support a model in which E2F1/Sd interactions promote apoptosis, whereas Yki/Sd interactions suppress apoptosis, and E2F1 and Yki compete for the interaction with Sd.

Genome-wide Interactions between Yki and E2F1 {#sec2.7}
---------------------------------------------

To investigate whether E2F1/Yki competition is restricted to a few targets, such as *Diap1* and *ex*, or is a broader phenomenon, we used a combination of DamID-seq ([@bib40], [@bib5], [@bib55]) and RNA-seq to map Yki targets genome-wide in wing discs and assess how these are affected by E2F1. Using DamID-seq, we identified 4,986 binding sites with strong Dam-Yki binding (log2 fold change \>3, false discovery rate \[FDR\] \<0.001) when compared with a Dam-only control ([Table S1](#mmc2){ref-type="supplementary-material"}). The gene set associated with these binding sites had a very significant overlap (p \< 10^−72^, hypergeometric test) with a previous Yki ChIP study also performed on wing discs ([@bib37]) ([Figures 6](#fig6){ref-type="fig"}A and 6B). Using RNA-seq, we identified 281 genes that could be upregulated by *yki* overexpression and downregulated by depletion of *yki* using RNAi ([Figure 6](#fig6){ref-type="fig"}C; [Tables S2](#mmc3){ref-type="supplementary-material"} and [S3](#mmc4){ref-type="supplementary-material"}, FDR \<0.05). As a way to identify potentially direct transcriptional targets of Yki, the RNA-seq datasets were cross-compared with our Yki DamID data and the Yki ChIP data of Oh et al. Among 281 genes transcriptionally regulated by Yki, 116 had Yki binding sites as assayed by both DamID and ChIP ([Figure 6](#fig6){ref-type="fig"}C and [Table S4](#mmc5){ref-type="supplementary-material"}). This set of 116 genes defines likely direct transcriptional targets of Yki. Gene ontology analysis suggested that the above-mentioned 116 genes mediate a broad range of functions, including imaginal disc development and growth, regulation of programmed cell death, tissue homeostasis, stem cell fate commitment, etc ([Table S5](#mmc6){ref-type="supplementary-material"}).Figure 6Genome-wide Interactions between Yki and E2F1(A) Histogram showing the distribution of Yki ChIP-seq peaks ([@bib37]) to Yki DamID-seq peaks (red) and also the distance distribution of random peaks (by shuffling the ChIP-seq peaks in the genome) to Yki DamID-seq peaks as background (gray). Compared with the random peaks, the ChIP-seq peaks were significantly colocalized with DamID-seq peaks (p \< 2.2×10^−16^, Kolmogorov-Smirnov test). The MACS software was used to identify the ChIP binding peaks of Yki. The p value cutoff was set to 10^−5^. If more than half the length of one peak region overlapped with an annotated gene, the peak was assigned to that gene.(B) Venn diagram showing the overlap between Yki DamID-seq targets and Yki ChIP-seq targets in wing discs. The significance of overlap (p \< 10^−72^) was assessed by hypergeometric test.(C) Venn diagram showing the overlap of genes upregulated by *yki* overexpression, downregulated by *yki*^*RNAi*^ and associated with significant Yki binding. The significance of overlap (p = 2.1 × 10^−39^) was assessed by hypergeometric test. The overlapping 116 genes were categorized as direct Yki targets.(D) Venn diagram showing the overlap between the 116 genes identified in (C) and genes downregulated by *E2f1* overexpression (p = 1.8 × 10^−6^, hypergeometric test).(E) Heatmap displaying alterations in mRNA expression of 22 genes shown in (D) after altering *yki* or *E2f1* expression. Each row represents one gene. Normalized gene expression level is colored blue to red to indicate low to high. Genes marked in red have been shown to be differentially regulated during implantation and wound-induced wing disc regeneration process ([@bib1]).

In order to determine which Yki targets could be modulated by E2F1, we also generated RNA-seq data following overexpression of E2F1. This experiment identified 3,740 genes that were either activated or repressed by overexpressed E2F1 ([Tables S6](#mmc7){ref-type="supplementary-material"} and [S7](#mmc8){ref-type="supplementary-material"}, FDR \<0.05). By comparing these 116 direct Yki targets with data from RNA-seq profiling following E2F1 overexpression ([Table S7](#mmc8){ref-type="supplementary-material"}), we identified 22 genes, including *Diap1*, that were transcriptionally downregulated by *E2f1* overexpression ([Figures 6](#fig6){ref-type="fig"}D and 6E, p = 1.8 × 10^−6^, hypergeometric test). Interestingly, 14 of these 22 genes (red labels, [Figure 6](#fig6){ref-type="fig"}E) have been shown to be differentially regulated during implantation and wound-induced wing disc regeneration ([@bib1]). This suggests that E2F1-regulated Yki activity might play a role in damage-induced regeneration. In addition, *jaguar (jar)*, a recently identified Hippo pathway regulator ([@bib24]), was found in this 22-gene list, suggesting another mechanism of feedback regulation in Hpo signaling. Altogether, our DamID-seq and RNA-seq analyses confirm that E2F1-Yki interactions affect many target genes and are likely to have diverse biological effects.

Human E2F1 Suppresses YAP Activity by Interacting with TEAD1 {#sec2.8}
------------------------------------------------------------

We next examined whether the Yki/E2F1 interaction we describe in *Drosophila* is conserved in mammalian cells. *Drosophila E2f1* is an ortholog of human *E2f1*, *E2f2*, and *E2f3*. First, we generated transgenic flies carrying these human genes and tested their roles in regulating the Hippo pathway in *Drosophila* wing discs. We found that overexpression of either *hE2f1* or *hE2f2* dramatically reduced *Diap1-GFP* levels ([Figures 7](#fig7){ref-type="fig"}A--7B′). Overexpression of *hE2f3a* and *hE2f3b*, however, showed no repression of Yki activity ([Figures 7](#fig7){ref-type="fig"}C and 7D). These data suggest that human *E2f1* and *E2f2* are functionally conserved orthologs of *Drosophila E2f1* with respect to the ability to regulate Yki activity.Figure 7Human E2F1 Suppresses YAP Activity by Interacting with TEAD1(A--D) *UAS-hE2f1, 2, 3a, 3b* were overexpressed driven by *hh*^*ts*^, respectively. The larvae were raised at 18°C, and then shifted to 29°C for 24 hr before dissection in third-instar stage. White asterisks (A and B) indicate normal expression of *diap1-GFP* in anterior compartments, and yellow asterisks (A and B) indicate altered expression of *diap1-GFP* upon human *E2f1* (or human *E2f2*) overexpression in posterior compartments.(E) MCF7 cells were infected by *hE2F1* adenovirus. The qPCR assay showed that hE2F1 represses the mRNA levels of *CTGF* and *Cyr61*. Values represent means ± SEM (n = 3, t test, ^∗∗^p \< 0.01).(F and G) ChIP assays were performed in HeLa cells transfected with indicated plasmids. Chromatin was precipitated by control IgG or endogenous YAP antibody. The enrichment of ChIP products on *CTGF* and *CDK6* promoters were measured by real-time PCR (mean ± SEM, n = 3, t test, ^∗^p \< 0.05, ^∗∗∗^p \< 0.001).(H) The endogenous coIP of hE2F1 and TEAD1 was conducted in HeLa cells.(I and J) HEK293T cells were transfected with indicated plasmids and subjected to immunoprecipitation. hE2F1 coIPed with Flag-TEAD1 (I) but not Myc-YAP (J).(K) Increasing concentrations (dose, 0.1--1.5 μg) of hE2F1 reduced the amount of Flag-TEAD1 pulled down by Myc-Yki.(L) The model shows that the interaction in which E2F1 suppresses Yki/YAP target gene expression by interfering with Yki/YAP binding to Sd/TEAD is functionally conserved between humans and *Drosophila*. This regulation has significant effects on apoptosis, organ growth, and homeostasis. A question mark indicates uncertainty or yet-to-be-established finding.

Next, we examined the ability of *hE2f1* to inhibit the human ortholog of Yki, YAP, in mammalian cells. Overexpression of *hE2f1* in MCF7 cells significantly inhibited the expression of *CTGF* and *Cyr61*, which are endogenous downstream targets of YAP ([Figure 7](#fig7){ref-type="fig"}E). Further, ChIP assays showed that overexpression of *hE2f1* in HeLa cells significantly reduced the binding of YAP on its characterized targets, *CTGF* and *CDK6* ([Figures 7](#fig7){ref-type="fig"}F and 7G). Consistently, coIP assays showed that the hE2F1 protein interacts with the Sd homolog TEAD1 ([Figures 7](#fig7){ref-type="fig"}H and 7I) but not YAP ([Figures 7](#fig7){ref-type="fig"}J), and that hE2F1 interferes with YAP binding to TEAD1 in a dose-dependent manner ([Figure 7](#fig7){ref-type="fig"}K), just as observed for the *Drosophila* orthologs of these genes. Taken together, these results indicate that the interaction in which E2F1 suppresses Yki/YAP target gene expression by interfering with Yki/YAP binding to Sd/TEAD is functionally conserved between humans and *Drosophila* ([Figure 7](#fig7){ref-type="fig"}L).

Discussion {#sec3}
==========

The Hippo and RB-E2F signaling pathways are both highly conserved, and both regulate cell proliferation and survival in diverse scenarios. The overlapping functions of these two pathways suggest that their activities should be coordinated to regulate cell fates. However, few interactions between these pathways have been reported. In this study, we uncover a previously unknown mechanism in which RBF/RB, via E2F1, regulates Hippo signaling by modulating the formation of Yki/Sd (YAP/TEAD1) activator complexes. We show that *Drosophila* E2F1 counteracts the binding of Yki, a coactivator, to its DNA-binding partner, Sd. Yki/Sd complexes simulate transcription of target genes (*Diap1*, *ex*, and *ban*, etc) that promote cell growth and survival, whereas E2F1 releases Yki:Sd association and suppresses Yki target gene expression, thereby promoting apoptosis and other developmental defects. RBF modified these effects by reducing the activity of the E2F1/Sd repressor complexes, potentially also by a competitive mechanism. This competition mechanism is similar to that reported for Tgi, which was demonstrated to play a role in Sd-mediated default repression ([@bib14], [@bib22]). To determine how specific E2F1's effects on Hippo signaling are, we examined whether E2F1 regulates the activity of four other signaling pathways: Notch (N), Wingless (Wg), Hedgehog (Hh), and Decapentaplegic (Dpp). Like Hpo signaling, each of these pathways is important for wing development. Tests in wing discs using reporter genes for these pathways did not reveal any modifying effects of E2F1 ([Figures S5](#mmc1){ref-type="supplementary-material"}A--S5D″). These data suggest that E2F1's ability to repress Yki activity is a pathway-specific mechanism, rather than a general transcriptional effect.

The *Drosophila* genome contains two *E2f* genes (*E2f1* and *E2f2*). E2F1 (a functionally conserved homolog of mammalian E2F1-3) acts primarily as a transcriptional activator, whereas E2F2 (a functionally conserved homolog of mammalian E2F4-5) represses transcription ([@bib12]). While either RB loss of function or E2F1 gain of function may sensitize cells to apoptosis, the mechanisms underlying these effects are not well understood. In the *Drosophila* wing, dE2F1-induced apoptosis is sensitive to the levels of the anti-apoptotic factor Diap1 ([@bib31]). Since *Diap1* is by many accounts a downstream target of Hippo signaling, this raises the possibility that RB/E2F1 might regulate apoptosis by controlling this branch of the Hippo pathway. Indeed, our clonal analysis showed that overexpression of *Diap1* successfully restored the reduced clone size caused by *E2f1* overexpression, strongly indicating that RBF/E2F1-regulated apoptosis depends on the balance of pro-apoptotic E2F1/Sd complexes and anti-apoptotic Yki/Sd complexes. A previous report showed that the induction of apoptosis in *Drosophila* by RBF depends on E2F2 ([@bib7]). However, we observed no suppression of *Diap1* expression by E2F2, suggesting a specific role for RB-E2F1 signaling. This is consistent with previous findings showing that E2F-induced apoptosis is associated with some E2F family members (human and *Drosophila* E2F1) but not with others ([@bib26], [@bib29]). Further, our data confirmed previous observations suggesting that *E2f1* is a downstream target of Hippo signaling ([@bib13], [@bib35]) ([Table S2](#mmc3){ref-type="supplementary-material"}). This suggests that Yki, via E2F1, might be able to suppress its own activity. Overall the results we present are consistent with a model in which E2F1 acts as a repressor of Yki target gene expression. While a previous study reported that Yki/Sd and E2F1 can activate a set of common targets (e.g., *Dachs*, *PCNA*, and *Dp*) in eye discs ([@bib34]), our analysis did not find that these three genes were activated by both Yki/Sd and E2F1 in wing discs ([Figures S6](#mmc1){ref-type="supplementary-material"}A--S6H′, [Tables S2](#mmc3){ref-type="supplementary-material"} and [S6](#mmc7){ref-type="supplementary-material"}). These discrepancies are likely due to differences in cell type, which can have large effects on transcriptional outputs.

Our *in vivo* and *in vitro* data show that competitive interactions between E2F and Yki/Sd require E2F1's DNA-binding activity. This raises the possibility that E2F1-mediated repression of Yki targets might be mediated through the transcriptional regulation of other unknown repressor(s), which thereby repress Yki activity via an indirect mechanism. To address this, we generated a transactivation domain-defective mutant form of *E2f1*, *E2f1*^*TDM*^. This mutant still showed strong inhibition on *Diap1* expression, suggesting that the inhibition of Yki targets by E2F1 cannot be attributed to effects via E2F1's transcriptional target(s). To further test this, we performed *in vitro* binding assays. These experiments showed that purified E2F1 and Sd physically interact quite strongly *in vitro*. Moreover, this *in vitro* interaction could be diminished by the presence of Yki ([Figure S3](#mmc1){ref-type="supplementary-material"}J). Taken together, these data are consistent with the idea that E2F1 and Yki compete for Sd binding through direct protein-protein interaction. The fact that the E2F DNA-binding domain is required may indicate the involvement of a DNA bridging interaction or may suggest that E2F1 needs to bind to DNA to take on an active conformation that interacts with Sd. Through analyzing published E2F1 ChIP-chip data ([@bib23]) and Yki ChIP-seq data ([@bib37]), we found that E2F1 and Yki typically bind in close proximity to each other on common target loci ([Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B). These data suggest that the adjacent binding of E2F1 and Yki/Sd complex on certain regions of the genome may facilitate the negative effect of E2F1 on Yki. However, given our current data, we still cannot rule out the possibility that E2F1 recruits transcriptional repressor(s) to Yki targets, thereby repressing their expression.

To better understand whether the E2F1/Yki interaction we discovered is restricted to a few genes or is a broader phenomenon, we used a combination of RNA-seq and DamID-seq to investigate how Yki targets genome-wide could be affected by E2F1 activity. Our DamID-seq and RNA-seq data define a set of Yki targets that can be negatively regulated by E2F1. Many of these genes have been shown to be differentially regulated during implantation and wound-induced wing disc regeneration, suggesting that E2F1 might play an important role in regulating YAP-controlled regeneration process. Importantly, our data demonstrate that the E2F1/Yki competition is an evolutionarily conserved mechanism. First, overexpression of *hE2f1* or *hE2f2* in *Drosophila* wing discs dramatically suppressed expression of the Yki target *Diap1*. In addition, hE2F1 competed with YAP for binding to the Sd ortholog TEAD1, and effectively suppressed YAP target gene expression in human cells. While it has been previously reported that ectopic expression of h*E2f1*, h*E2f2*, and h*E2f3* induce apoptosis ([@bib6]), our experiments suggest that only hE2F1 and hE2F2 retain the ability to repress YAP target genes. Overall, our study describes a previously unappreciated mechanism in which RB/E2F1 activity modifies Hippo signaling by modulating the formation of Yki/Sd activator and E2F1/Sd repressor complexes and thereby influences organ size control and tissue homeostasis.

Since cancerous malignancies are caused by multiple mutations ([@bib27]), a major challenge in the study of tumorigenesis is to determine the relative contribution of individual molecular lesions. While *Rb* is often mutated or inactivated in cancers, the singular loss of *Rb* function in mice increases apoptosis in some tissues, rather than leading to tumorigenesis ([@bib6]). Our discovery that E2F1 can suppress YAP activity provides one possible explanation for this conundrum. A previous study showed that low Wnt activity in *Rb*-deficient cells was due to E2F1-mediated abrogation of β-catenin target gene expression and induction of β-catenin degradation ([@bib30]). The authors concluded that repression of β-catenin by E2F1 may contribute to E2F1-induced apoptosis. In conjunction with the findings reported here, we suggest that a block to apoptosis may be necessary for *Rb* mutations to contribute to tumorigenesis and that increased YAP activity may be one way to achieve this. Emerging evidence shows that the Hippo pathway is deregulated in many human cancers ([@bib61]). However, it remains unknown whether the deregulation of the Hippo pathway contributes to the malignancy of *Rb*-deficient tumors by suppressing apoptosis. Although elevated levels and nuclear localization of YAP/TAZ occur in various human cancers, mutations in Hippo pathway genes are rare ([@bib61], [@bib19]). This indicates that the Hippo pathway may be regulated by many other pathways influencing oncogenesis. However, it is still unknown whether Yki activity is reduced to relatively low levels in cancer cells with defective RB function, or whether other oncogenic pathways bypass Hippo signaling to block RB mutation-induced apoptosis. This will be an interesting avenue for future study.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Mouse α-β-galactosidasePromegaCat\#Z3781; RRID: [AB_430877](nif-antibody:AB_430877){#intref0010}Rat α-CiDHSB2A1; RRID: [AB_2109711](nif-antibody:AB_2109711){#intref0015}Guinea pig α-E2F1Xiaolin Bi (DMU)N/ARabbit α-E2F1Xiaolin Bi (DMU)N/AMouse α-EnDHSB4D9; RRID: [AB_528224](nif-antibody:AB_528224){#intref0020}Mouse α-Diap1Bruce Hay (Caltech)N/ARabbit α-YkiLei Zhang (SIBCB)N/ARabbit α-hE2F1CSTCat\#3742; RRID: [AB_2096936](nif-antibody:AB_2096936){#intref0025}Rabbit α-hE2F2Santa Cruz BiotechnologyCat\#Sc-632; RRID: [AB_2277708](nif-antibody:AB_2277708){#intref0030}Rabbit α-Cleaved Caspase-3CSTCat\#9661; RRID: [AB_2341188](nif-antibody:AB_2341188){#intref0035}Chicken α-GFPThermo Fisher ScientificCat\#A10262; RRID: [AB_2534023](nif-antibody:AB_2534023){#intref0040}Rabbit α-PH3MilliporeCat\#06-570; RRID: [AB_310177](nif-antibody:AB_310177){#intref0045}Mouse α-WgDHSB4D4; RRID: [AB_528512](nif-antibody:AB_528512){#intref0050}Guinea pig α-Sens([@bib65])N/AMouse α-DllXinhua Lin (CCHMC)N/AMouse α-PtcDHSBApa 1.3; RRID: [AB_528441](nif-antibody:AB_528441){#intref0055}Mouse α-SmoDHSB20C6; RRID: [AB_528472](nif-antibody:AB_528472){#intref0060}Rabbit α-Sal([@bib65])N/ARat α-DachsDavid Strutt (University of Sheffield)N/AMouse α-DpNicholas Dyson (MGH)N/AMouse α-V5Thermo Fisher ScientificCat\#MA5-15253; RRID: [AB_10977225](nif-antibody:AB_10977225){#intref0065}EZview™ Red α-HA Affinity GelSigma-AldrichCat\#E6779; RRID: [AB_10109562](nif-antibody:AB_10109562){#intref0070}EZview™ Red α-Flag Affinity GelSigma-AldrichCat\#F2426; RRID: [AB_2616449](nif-antibody:AB_2616449){#intref0075}Mouse α-MycMBL InternationalCat\#M047-3; RRID: [AB_591112](nif-antibody:AB_591112){#intref0080}Rabbit α-YAPABclonalCat\#A1002Mouse α-FlagSigma-AldrichCat\#F4042; RRID: [AB_439686](nif-antibody:AB_439686){#intref0085}Mouse α-HASanta Cruz BiotechnologyCat\# sc-7392; RRID: [AB_627809](nif-antibody:AB_627809){#intref0090}Mouse α-TEF-1(TEAD1)BD BiosciencesCat\#610923; RRID:[AB_398238](nif-antibody:AB_398238){#intref0095}Mouse α-GAPDHCWBiotechCat\#CW0100MMouse α-β-actinProteintech GroupCat\#60008-1-Ig; RRID: [AB_2289225](nif-antibody:AB_2289225){#intref0100}**Bacterial and Virus Strains**TOP10CWBiotechCat\#CW0807BL21(DE3)CWBiotechCat\#CW0809**Chemicals, Peptides, and Recombinant Proteins**DAPIThermo Fisher ScientificCat\#D1306; RRID:[AB_2629482](nif-antibody:AB_2629482){#intref0105}Proteinase KRocheCat\#03115828001RNase AQIAGENCat\#19101T4 DNA ligaseNEBCat\#M0202LDpnINEBCat\#R0176LDpnIINEBCat\#R0543LSau3AINEBCat\# R0169L**Critical Commercial Assays**QIAquick PCR purification kitQIAGENCat\#28106Qubit dsDNA HS Assay KitThermo Fisher ScientificCat\#Q32851TruSeq DNA PCR-Free Library Preparation KitIlluminaCat\#FC-121-3001 and FC-121-3002**Experimental Models: Cell Lines***Drosophila* S2 cellsThermo Fisher ScientificCat\#R69007HEK293TATCCCat\#CRL-3216HeLaATCCCat\#CCL-2MCF7ATCCCat\#HTB-22**Experimental Models: Organisms/Strains***Drosophila: UAS-Rbf*^*RNAi*^BDSC36744*Drosophila: UAS-Rbf*BDSC50747*Drosophila: UAS-E2f1*^*RNAi*^BDSC27564*Drosophila: UAS-Dp*^*RNAi*^BDSC33372*Drosophila: UAS-E2f1+Dp (II)*BDSC4774*Drosophila: UAS-E2f1+Dp (III)*BDSC4770*Drosophila: UAS-P35*BDSC5072*Drosophila: ban-LacZ*BDSC10154*Drosophila: UAS-hpo*^*RNAi*^BDSC33614*Drosophila: UAS-yki*^*RNAi*^BDSC31965*Drosophila: UAS-sd*^*RNAi*^BDSC29352*Drosophila: UAS-E2f2*FlyORFF000069*Drosophila: Rbf*^*14*^*FRT*^*19A*^([@bib3])N/A*Drosophila: UAS-GFP-E2f1*([@bib3])N/A*Drosophila: UAS-GFP-E2f1*^*PIP3A*^([@bib3])N/A*Drosophila: UAS-cycD, cdk4*([@bib3])N/A*Drosophila: PCNA-GFP*([@bib3])N/A*Drosophila: MARCM*^*82B*^Tao Wang (NIBS)N/A*Drosophila: EGUF*^*19A*^Tao Wang (NIBS)N/A*Drosophila: UAS-wts*^*RNAi*^VDRC106174*Drosophila: sd-lacZ*Georg Halder (KU Leuven)N/A*Drosophila: Diap1-GFP3.5*([@bib64])N/A*Drosophila: Diap1-lacZ*([@bib64])N/A*Drosophila: act\>CD2\>Gal4*([@bib64])N/A*Drosophila: ex-lacZ*([@bib64])N/A*Drosophila: UAS-yki*([@bib64])N/A*Drosophila: Diap1-lacZ*^*2B*^([@bib58])N/A*Drosophila: Diap1-lacZ*^*2B2C*^([@bib58])N/A*Drosophila: UAS-E2f1*This paperN/A*Drosophila: UAS-E2f1*^*E259*^This paperN/A*Drosophila: UAS-E2f1*^*D296A*^This paperN/A*Drosophila: UAS-V5-E2f1*^*TDM*^This paperN/A*Drosophila: UAS-hE2f1*This paperN/A*Drosophila: UAS-hE2f2*This paperN/A*Drosophila: UAS-hE2f3a*This paperN/A*Drosophila: UAS-hE2f3b*This paperN/A*Drosophila: UAS-Dam-yki*This paperN/A*Drosophila: UAS-Dam*Andrea Brand (The Gurdon Institute)N/A*Drosophila: hhGal4, tubGal80*^*ts*^This paperN/A*Drosophila: nubGal4, tubGal80*^*ts*^This paperN/A*Drosophila: Myo1AGal4, tubGal80*^*ts*^This paperN/A*Drosophila: apGal4, tubGal80*^*ts*^This paperN/A**Oligonucleotides**E2f1 mutagenesis primersThis paper, [Table S8](#mmc9){ref-type="supplementary-material"}N/AqRT-PCR primersThis paper, [Table S8](#mmc9){ref-type="supplementary-material"}N/AChIP-PCR primers([@bib41], [@bib60], [@bib59]), [Table S8](#mmc9){ref-type="supplementary-material"}N/AOligos used for DamID-Seq([@bib56]), [Table S8](#mmc9){ref-type="supplementary-material"}N/A**Recombinant DNA**Plasmid: pUASTattB-E2f1This paperN/APlasmid: pUASTattB-E2f1^E259^This paperN/APlasmid: pUASTattB-E2f1^D296A^This paperN/APlasmid: pUASTattB-V5-E2f1^TDM^This paperN/APlasmid: pUASTattB-hE2f1This paperN/APlasmid: pUASTattB-hE2f2This paperN/APlasmid: pUASTattB-hE2f3aThis paperN/APlasmid: pUASTattB-hE2f3bThis paperN/APlasmid: pUASTattB-V5-DpThis paperN/APlasmid: pUASTattB-V5-RbfThis paperN/APlasmid: pET-28a-His-YkiThis paperN/APlasmid: pGEX-4T-1-GST-SdThis paperN/APlasmid: pcDNA6A-Myc-His-E2f1This paperN/APlasmid: pCMV-Flag- hE2f1This paperN/APlasmid: pUASTattB-LT3-NDamAndrea Brand (The Gurdon Institute)N/APlasmid: pUASTattB-LT3-Dam-ykiThis paperN/APlasmid: pCMV-Flag-TEAD1This paperN/APlasmid: pCMV-Flag-ykiThis paperN/APlasmid: pCMV-Myc-YapThis paperN/APlasmid: pUAST-Myc-ykiLei Zhang (SIBCB)N/APlasmid: pUAST-HA-SdLei Zhang (SIBCB)N/APlasmid: pUAST-HA-Sd-NLei Zhang (SIBCB)N/APlasmid: pUAST-HA-Sd-CLei Zhang (SIBCB)N/APlasmid: arm-Gal4Xinhua Lin (CCHMC)N/APlasmid: pML-Gal4Xinhua Lin (CCHMC)N/A**Software and Algorithms**Bowtie 2([@bib25])<http://bowtie-bio.sourceforge.net/bowtie2/index.shtml>Damidseq_pipeline([@bib28])<https://owenjm.github.io/damidseq_pipeline/>TopHat2 version 2.0.9([@bib2], [@bib21])N/AHTSeq python package<http://htseq.readthedocs.io>N/AR packages<https://www.r-project.org>N/ADNAMAN version 6Lynnon Biosoft<http://www.lynnon.com>Prism 7GraphPad SoftwareRRID:SCR_002798ImageJ<https://fiji.sc>N/A

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Bruce A. Edgar (<bruce.edgar@hci.utah.edu>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

All fly strains were kept on standard fly medium at 25°C. For temperature shift experiments, larvae were raised at 18°C prior to shifting to the temperature conditions described in the corresponding figure legends and [Method Details](#sec4.4){ref-type="sec"}. Imaginal discs were dissected from 3^rd^ instar larvae of both sexes. Midguts were dissected from adult females.

Method Details {#sec4.4}
--------------

### *E2f1* Mutagenesis {#sec4.4.1}

Different *E2f1* mutations (*E2f1*^*E259*^, *E2f1*^*D296A*^ and *E2f1*^*TDM*^) were generated using Site-Directed mutagenesis kit (Thermo Fisher Scientific). Primers used for *E2f1* mutagenesis are shown in [Table S8](#mmc9){ref-type="supplementary-material"}.

### Cell Culture {#sec4.4.2}

HeLa, HEK293T and MCF7 cell lines were cultured in DMEM supplemented with 10% FBS (Gibco) in 5% CO~2~ atmosphere at 37°C. Plasmid transfection was conducted with Lipofectamine (Thermo Fisher Scientific). *Drosophila* S2 cells were maintained at 25°C in Schneider's medium (Gibco) supplemented with 10% FBS (Gibco).

### Immunostaining {#sec4.4.3}

After dissection, samples were fixed in PBS with 4% paraformaldehyde (20 min for wing discs or 30 min for midguts), washed in PBS with 0.1% Triton X-100, and blocked in PBS with 0.1% Triton X-100 and 10% NGS for at least 30 min at room temperature. All samples were then stained with primary antibodies at 4°C overnight with the following dilutions: mouse α-β-gal (Promega, 1:500), rat α-Ci (DHSB, 1:20), guinea pig α-E2F1 (X. Bi, 1:200), mouse α-En (DHSB, 1:20), mouse α-Diap1 (B. Hay, 1:200), rabbit α-Yki (L. Zhang, 1:50), rabbit α-hE2F1 (CST, 1:100), rabbit α-hE2F2 (Santa Cruz Biotechnology, 1:100), rabbit α-Cleaved Caspase-3 (CST, 1:100), chicken α-GFP (Thermo Fisher Scientific, 1:1000), rabbit α-PH3 (Millipore, 1:1000), mouse α-Wg (DHSB, 1:5), guinea pig α-Sens ([@bib65]), mouse α-Dll (X. Lin, 1:200), mouse α-Ptc (DHSB, 1:50), mouse α-Smo (DHSB, 1:100), rabbit α-Sal ([@bib65]), rat α-Dachs (D. Strutt, 1:500) and mouse α-Dp (N. Dyson, 1:5). DAPI (Thermo Fisher Scientific, 1:1000) was used to label nuclei. Staining was detected by Alexa Fluor 488, 568, or 633 conjugated species appropriate secondary antibodies (Thermo Fisher Scientific, 1:1000).

### Co-immunoprecipitation and Western Blot {#sec4.4.4}

For co-immunoprecipitation, cell lysates were prepared in the lysis buffer (50mM Tris-HCl, pH7.5; 150mM NaCl, 1mM EDTA, 1mM EGTA, 5mM Na~4~P~2~O~7~, 25mM NaF, 1% Triton X-100) with protease inhibitors (cocktail) on ice for 30min. After clarification by centrifugation, the lysates were incubated for 2-6h at 4 °C with antibodies pre-bound to protein A/G agarose beads. Beads were washed four times with washing buffer (50mM Tris-HCl, pH7.5; 150mM NaCl, 1mM EDTA, 1mM EGTA, 5mM Na~4~P~2~O~7~, 25mM NaF, 0.5% Triton X-100), and eluted in 1x SDS loading buffer. Eluted samples were analyzed by western blotting. Antibodies used for immunoprecipitation were: mouse α-Myc (MBL International), mouse α-V5 (Thermo Fisher Scientific), mouse α-TEAD1 (BD Biosciences), EZview™ Red Anti-HA Affinity Gel (Sigma-Aldrich) and EZview™ Red Anti-Flag Affinity Gel (Sigma-Aldrich). Primary antibodies used for western blot were: rabbit α-E2F1 (X. Bi, 1:2000), mouse α-Flag (Sigma-Aldrich, 1:10000), rabbit α-Yki (L. Zhang, 1:5000), mouse α-TEAD1 (BD Biosciences, 1:500), mouse α-HA (Santa Cruz Biotechnology, 1:1000), mouse α-V5 (Thermo Fisher Scientific, 1:20000), mouse α-Myc (MBL International, 1:2000), rabbit α-hE2F1 (CST, 1:1000), mouse α-GAPDH (CWBiotech, 1:1000) and mouse α-β-actin (Proteintech Group, 1:5000).

### qRT-PCR {#sec4.4.5}

Quantitative real-time PCR was performed using 2×SYBR Green PCR master mix (CWBiotech) in an Agilent Mx3005P qRT-PCR system. The mRNA levels were normalized to rp49 (for wing disc) or GAPDH (for cell line) expression levels. Primers used for qRT-PCR are listed [Table S8](#mmc9){ref-type="supplementary-material"}.

### ChIP Assays {#sec4.4.6}

Cells were cultured in 15cm dishes (about 90% density), cross-linked with 1% formaldehyde for 15min in room temperature and then sonicated to an average fragment size of ∼600 bp. Control IgG or specific antibodies, including mouse anti-Myc (MBL), rabbit anti-YAP (Abclonal) were used in each ChIP assay. The immunoprecipitated DNA was quantified using real-time PCR. All values were normalized to the input. Primers for analyzing the ChIP DNA are shown in [Table S8](#mmc9){ref-type="supplementary-material"} ([@bib41], [@bib60], [@bib59]).

### DamID-Seq and Data Analysis {#sec4.4.7}

The *yki* cDNA was cloned into pUASTattB-LT3-NDam (A. Brand) and transgenic flies were generated. Flies carrying the UAS-Dam alone transgene (A. Brand) were used as a control for nonspecific Dam activity. The expression of all transgenes used in DamID-Seq was driven by the *nub*^*ts*^ system. Larvae were raised at 18°C, and then shifted to 29°C for 24 hours before dissection of third instar wing discs in ice-cold PBS. Around 100 wing discs were pooled in 200 μl of lysis (TENS) buffer. 2 μl Proteinase K (20 mg/ml, Roche) was added to each sample before homogenization followed by incubation for 7 hours at 65°C. Samples were incubated for 30 min at 37°C with 0.5 mg/ml RNase A (QIAGEN) before phenol/chloroform extraction of genomic DNA (gDNA). Genomic DNA from each genotype (∼2.5 μg) was digested with DpnI (NEB) for 16 hr at 37°C in a total volume of 10 μl. 5 μl of DpnI-digested gDNA was ligated to 40 pmol of a double-stranded unphosphorylated adaptor using T4 DNA ligase (NEB) in a total volume of 20 μl. The adaptor was generated by mixing equal volumes of oligo AdRt (100 μM) (5'-CTAATACGACTCACTATAGGGCAGCGTGGTCGCGGCCGAGGA-3') and oligo AdRb (100 μM) (5'-TCCTCGGCCG-3') ([@bib56]), at 100°C for 1 min, followed by cooling to RT. To prevent amplification of DNA fragments containing unmethylated GATCs, the adaptor-ligated DNA was cut with DpnII (NEB) for 2 hr at 37°C in a total volume of 80 μl. 20 μl of DpnII-cut DNA was amplified by PCR in a total volume of 80 μl using the primer (5'-GGTCGCGGCCGAGGATC-3') designed to fit to the adaptor ([@bib56]). 3-3.5 μg of PCR product was diluted to 45 μl total volume and sonicated to produce 300-400 bp fragments. The sonicated DNA was then digested by Sau3AI at 37°C overnight to remove the adaptors, as Sau3AI can cut the both methylated and non-methylated GATC sites. The Sau3AI-digested product was purified using a QIAquick PCR purification kit (QIAGEN). Purified product was quantified by Qubit dsDNA HS Assay Kit (Thermo Fisher Scientific). The sequencing library was prepared using a TruSeq DNA PCR-Free Sample Preparation kit (Illumina).

DamID-Seq raw reads were mapped to the *Drosophila* genome (dm6, [genome.ucsc.edu](http://genome.ucsc.edu){#intref0145}) using Bowtie 2 ([@bib25]) using default settings. Unmapped reads and reads with a mapping quality score \<10 were excluded for downstream analysis. The retained reads were extended 300 base pair toward the 3'-end, and the resulting bam files were subjected to the damidseq_pipeline analysis ([@bib28]) with parameters \--bamfiles \--bins=75 \--max_norm_value=100 \--min_norm_value=-100 \--norm_method=kde \--qscore1max=1 \--qscore1min=0.1 \--qscore2max=1. In brief, the method determined the best normalization factor between Dam-fusion and Dam-only samples based on Gaussian kernel density estimation, and determined the optimal number of pseudo-counts added to both samples in order to reduce background noise. The pipeline yielded log2-transformed read count ratios between Dam-fusion and Dam-only experiments in continuous non-overlapping 75-bp windows, which were then used for peak calling. The methods of peak calling and the false discovery rate (FDR) estimation were adapted from the previous publication ([@bib57]). In brief, all 75-bp windows with binding intensity (that is log2 read count ratios) above certain thresholds (here, quantiles from 0.95 to 0.99 with a 0.01 step) were listed and merged. To assess the FDR of these candidate peaks, the intensity values of all windows were randomly shuffled for 100 times, and the mean frequency of difference size of consecutive windows with intensity score above each threshold was calculated. In the shuffled dataset, the relationship between the number of consecutive windows and the frequency of observation such windows was log linear, and could thus be effectively modeled for any number of windows with linear regression. The FDR was calculated as the ratio of expected over observed peaks for different number of consecutive windows above a given intensity threshold. Annotation of significant peaks (FDR\<0.01) was based on overlaps between the peaks and genes annotated in the FlyBase or Ensembl databases.

### RNA-Seq and Data Analysis {#sec4.4.8}

The expression of each transgenes used in RNA-Seq was driven by the *nub*^*ts*^ system. Larvae were raised at 18°C, and then shifted to 29°C for 48 hours before dissection. Third instar wing discs of each samples were dissected for RNA-Seq according to standard protocols. Trimmomatic-processed raw RNA-Seq reads were mapped to the FlyBase *Drosophila* genome version 6.13 using TopHat2 version 2.0.9 ([@bib2], [@bib21]). Mapped reads were counted using HTSeq python package (<http://htseq.readthedocs.io>). Differentially expressed genes between experimental and control samples were determined using the MARS method (MA-plot-based method with random sampling model) from the R-package DEGseq, filtering for FDR\<0.05 and absolute change bigger than 50 reads as previously described ([@bib17]).

### Statistical Analysis {#sec4.4.9}

Statistical analyses were performed using the Graphpad Prism 7 software package. Statistical significance (P values) of all results were calculated by unpaired two-tailed Student\'s *t*-test. Statistical significance was denoted as follows: ^∗^ P\<0.05, ^∗∗^ P\<0.01, ^∗∗∗^ P\<0.001 and ^∗∗∗∗^ P\<0.0001.
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Supplemental Information {#app2}
========================

Document S1. Figures S1--S6Table S1. Yki Binding Peaks from Yki DamID-Seq, Related to Figure 6This table shows Yki binding peaks from Yki DamID-seq in third-instar wing disc cells overexpressing Dam-Yki fusion protein for 24 hr (cutoff: Log2 fold change of Dam-Yki/Dam-only \>3, FDR \<0.001).Table S2. Upregulated Genes Identified by RNA-Seq in Wing Discs upon Yki Overexpression, Related to Figure 6This table includes a list of genes that are significantly upregulated (FDR \<0.05) in third-instar wing disc cells overexpressing *yki* for 48 hr.Table S3. Downregulated Genes Identified by RNA-Seq in Wing Discs upon Yki Knockdown, Related to Figure 6This table includes a list of genes that are significantly downregulated (FDR \<0.05) in third-instar wing disc cells overexpressing *yki*^*RNAi*^ for 48 hr.Table S4. List of Genes Scored as Direct Yki Targets in Wing Discs, Related to Figure 6This list includes 116 genes that are differentially regulated both upon *yki* overexpression and *yki* knockdown and are also associated with one or more Yki binding peak. These genes are scored as direct transcriptional targets of Yki.Table S5. Functional Annotation of Direct Yki Targets, Related to Figure 6Gene ontology (GO) enrichment analysis was executed in R (version 3.1.1) using custom scripts with R packages GO.db, AnnotationDbi, and org.Dm.e.g.db. A number of 14,782 genes expressed in any conditions were taken as the background set, and the 116 genes were tested for enrichment in biological process (BP) ontology terms. p values were calculated with hypergeometric tests and thereafter adjusted with the Benjamini-Hochberg procedure (adjusted p values).Table S6. Upregulated Genes Identified by RNA-Seq in Wing Discs upon E2F1 Overexpression, Related to Figure 6This table includes a list of genes that are significantly upregulated (FDR \<0.05) in third-instar wing disc cells overexpressing *E2f1* for 48 hr.Table S7. Downregulated Genes Identified by RNA-Seq in Wing Discs upon E2F1 Overexpression, Related to Figure 6This table includes a list of genes that are significantly downregulated (FDR \<0.05) in third-instar wing disc cells overexpressing *E2f1* for 48 hr.Table S8. Primers and Oligos Used in This Study, Related to STAR MethodsThis table includes all of the primers and oligos used for *E2f1* mutagenesis, qRT-PCR, ChIP-PCR, and DamID-seq in this study.Document S2. Article plus Supplemental Information
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